Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Viking Therapeutics, Inc.

Viking Therapeutics, Inc. (VKTX) Stock Overview

Explore Viking Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

VKTX●NASDAQ
HealthcareBiotechnology
$33.89
$0.47(1.37%)
U.S. Market opens in 54h 40m

Viking Therapeutics, Inc. (VKTX)

Meyka AI Score

Z

Key Financials

Market Cap4B
P/E Ratio-7.25
EPS (TTM)$-4.66
ROE-0.95%
Fundamental Analysis

AI Price Forecasts

1 Month$21.32
3 Months$46.12
1 Year Target$32.17

VKTX Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Viking Therapeutics, Inc. (NASDAQ: VKTX) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Viking Therapeutics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of VKTX on the NASDAQ shows an RSI of 47.17, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $32.17 for the NASDAQ listing.

Key metrics behind Viking Therapeutics, Inc.'s NASDAQ-traded stock include a P/E ratio of -7.25 and a market capitalization of 4B. Combined with our AI analysis, these give both institutional and retail investors a clear view of VKTX on the NASDAQ.

Price Performance (NASDAQ: VKTX)

1-Day Change
-1.37%
5-Day Change
4.08%
1-Month Change
-10.70%
3-Month Change
10.46%
6-Month Change
9.22%
Year-to-Date (YTD) Change
-3.67%
1-Year Change
32.07%
3-Year Change
138.33%
5-Year Change
469.58%
All-Time (Max) Change
323.63%

Contact Information

https://www.vikingtherapeutics.com
858 704 4660
9920 Pacific Heights Boulevard, San Diego, CA, 92121

Company Facts

650 Employees
IPO DateApr 28, 2015
CountryUS
Actively Trading

Frequently Asked Questions